In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RaQualia Pharma Inc.

https://www.raqualia.com/

Latest From RaQualia Pharma Inc.

Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital

Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs. 

Financing Innovation

Takeda Gets GI Candidate – And Possibly Company – In Altos Deal

In the latest in a string of deals, Takeda's agreement to acquire global rights to Altos's gastroparesis candidate - and possibly the company itself - gives the Japanese giant another asset in its core gastrointestinal area.

BioPharmaceutical Asia Pacific

Japan Venture Taps ‘Deep Learning’ To Improve Drug Discovery

The Japanese peptide venture Interprotein is tapping into artificial intelligence technology with the hope of improving the efficiency and accuracy of its drug discovery efforts.

BioPharmaceutical Asia Pacific

RaQualia links with academia to boost research, cut costs

RaQualia Pharma sees a new collaboration with Nagoya University as having two main benefits: aiding its effort to find innovative new drugs and helping to control operational expenses.

Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AskAt Inc.
UsernamePublicRestriction

Register